-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $63

Benzinga·01/08/2026 16:51:51
Listen to the news
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $56 to $63.